NT-proBNP correlates with LVEF decline in HER2-positive breast cancer patients treated with trastuzumab [0.03%]
曲妥珠单抗治疗HER2阳性乳腺癌患者NT-proBNP与LVEF下降相关性研究
Nathalie I Bouwer,Crista Liesting,Marcel J M Kofflard et al.
Nathalie I Bouwer et al.
Background: Early identification of cardiac dysfunction by non-invasive imaging in HER2-positive breast cancer patients treated with trastuzumab is challenging. In particular multigated acquisition (MUGA) scan, which is m...
Increased skeletal intermuscular fat is associated with reduced exercise capacity in cancer survivors: a cross-sectional study [0.03%]
癌症幸存者骨骼肌间脂肪增多与运动能力下降有关：一项横断面研究
Kerryn W Reding,Peter Brubaker,Ralph D&#x;Agostino Jr et al.
Kerryn W Reding et al.
Background: Cancer survivors experience on average a 20% reduction in peak exercise capacity (VO2 peak) post-cancer treatment. Intermuscular fat (IMF) is a strong predictor of reduced exercise capacity in heart failure (H...
Systemic and cardiac susceptibility of immune compromised mice to doxorubicin [0.03%]
免疫功能低下的小鼠对阿霉素的系统和心脏易感性研究
Amanda J Favreau-Lessard,Hagen Blaszyk,Michael A Jones et al.
Amanda J Favreau-Lessard et al.
Background: Anthracycline chemotherapy is an effective and widely used treatment for solid tumors and hematological malignancies regardless of its known cardiotoxicity. The mechanisms of the cardiotoxicity are not fully u...
Upfront dexrazoxane for the reduction of anthracycline-induced cardiotoxicity in adults with preexisting cardiomyopathy and cancer: a consecutive case series [0.03%]
左佐茋酮 upfront 治疗成人癌症患者蒽环类药物引起的心肌病所致心脏毒性的连续病例系列研究
Sarju Ganatra,Anju Nohria,Sachin Shah et al.
Sarju Ganatra et al.
Background: Cardiotoxicity associated with anthracycline-based chemotherapies has limited their use in patients with preexisting cardiomyopathy or heart failure. Dexrazoxane protects against the cardiotoxic effects of ant...
Resting and exercise arterial dysfunction in anthracycline-treated adult survivors of childhood cancers [0.03%]
蒽环类药物治疗的儿童癌症成人幸存者的静息和运动时动脉功能障碍
Vivian Wing-Yi Li,Anthony Pak-Yin Liu,Karin Kar-Huen Ho et al.
Vivian Wing-Yi Li et al.
Background: Emerging evidence suggests potential arterial damage with the use of anthracycline-based chemotherapeutic regimens. We determined arterial function at rest and during exercise in anthracycline-treated adult su...
Tissue Doppler Imaging for anthracycline cardiotoxicity monitoring in pediatric patients with cancer [0.03%]
组织多普勒成像在癌症患儿蒽环类心脏毒性监测中的应用
Francesco Venturelli,Riccardo Masetti,Marianna Fabi et al.
Francesco Venturelli et al.
Background: Cardiotoxic effects of anthracycline therapy are a major cause of morbidity for childhood cancer survivors. The aim of this retrospective evaluation is to assess the efficacy of Tissue Doppler Imaging in the e...
Do current approaches to assessing therapy related adverse events align with the needs of long-term cancer patients and survivors? [0.03%]
当前用于评估与治疗相关的不良事件的方法是否符合长期癌症患者和幸存者的需求？
Syril D Pettit,Rebecca Kirch
Syril D Pettit
The increasing efficacy of cancer therapeutics means that the timespan of cancer therapy administration is undergoing a transition to increasingly long-term settings. Unfortunately, chronic therapy-related adverse health events are an unint...
Incidence and outcomes of cancer treatment-related cardiomyopathy among referrals for advanced heart failure [0.03%]
心脏衰竭患者癌症治疗相关心肌病的患病率和结局
Raquel Araujo-Gutierrez,Sergio H Ibarra-Cortez,Jerry D Estep et al.
Raquel Araujo-Gutierrez et al.
Background: Approximately 2-3% of patients undergoing advanced heart failure therapies such as left ventricular assist devices (LVAD) and orthotropic heart transplantation (OHT) have chemotherapy-related cardiomyopathy, a...
Recurrent heart failure with preserved ejection fraction associated with carfilzomib administration for multiple myeloma [0.03%]
复发性射血分数保留的心力衰竭与治疗多发性骨髓瘤的卡非佐米相关
Eric H Yang,Cynthia Courtney,Vinisha Garg et al.
Eric H Yang et al.
Carfilzomib, an epoxyketone proteasome inhibitor, has demonstrated improved progression-free survival in patients when used with standard treatment (lenalidomide and dexamethasone) in patients with relapsed multiple myeloma (MM). However, t...
Symptom practice guide for telephone assessment of patients with cancer treatment-related cardiotoxic dyspnea: Adaptation and evaluation of acceptability [0.03%]
电话评估癌症治疗相关性心毒性呼吸困难患者的症状实践指南：适应性和可接受性评价
F Kelly,S L Carroll,M Carley et al.
F Kelly et al.
Background: Patients with cancer treatment-related cardiotoxicity, which may manifest as heart failure (HF), can present with dyspnea. Nurses frequently assess, triage and offer self-care strategies to patients experienci...